Linked Life Data

6370875

Source:http://linkedlifedata.com/resource/pubmed/id/6370875

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1984-6-20
pubmed:abstractText
The efficacy of ceftazidime, a new broad-spectrum cephalosporin, active also against Pseudomonas aeruginosa, was tested in 19 patients suffering from severe, nonpulmonary localized or systemic infections, which were associated for the most part with concurrent diseases that often had already been unsuccessfully treated with other antibiotics. The treatment varied from 0.5 to 2 g three times daily by the intramuscular or intravenous routes for a minimum of 6 to a maximum of 16 days. Most of the microorganisms isolated were gram-negative (82.6%). Ceftazidime treatment proved efficacious in 17 of 19 cases (89.4%). No toxic effects were observed on hepatic, renal, and hematologic functions. Only in one case did a transient skin rash appear, which did not necessitate discontinuance of the treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0174-4879
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
167-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Use of ceftazidime in the treatment of severe localized and systemic infections.
pubmed:publicationType
Journal Article